MiNK Therapeutics reports Q4 net loss $7.8M; cash $19.6M at Dec 31, 2022

MiNK Therapeutics, Inc.

Net loss for Q4 2022: $7.8M ($0.23/share) vs $5.8M ($0.18) in Q4 2021.
Full year 2022 net loss $28.0M ($0.83/share) vs $30.2M ($1.16) in 2021.
Cash and equivalents $19.6M at Dec 31, 2022, down from $38.9M at Dec 31, 2021.
Cash used in operations FY2022 $18.9M; R&D expense rose to $23.1M from $14.0M.
Clinical update for agenT-797 in solid tumors to be presented at AACR April 2023; expansion into NSCLC/gastric cancer in 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MiNK Therapeutics, Inc. reported the year ended December 31, 2022 results: net income $28.0 million, EPS $0.83 per share.

Period: the year ended December 31, 2022
Net income: $28.0 million
EPS: $0.83 per share
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2022, was $28.0 million, or $0.83 per share compared to $30.2 million and $1.16 per share for the year ended December 31, 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MiNK Therapeutics, Inc. reported the quarter ended December 31, 2022 results: net income $7.8 million, EPS $0.23 per share.

Period: the quarter ended December 31, 2022
Net income: $7.8 million
EPS: $0.23 per share
Result: reported results

Exact text from the filing

Net loss for the quarter ended December 31, 2022, was $7.8 million or $0.23 per share, compared to a net loss for the same period of 2021 of $5.8 million or $0.18 per share.

View on SEC.gov

Browse all earnings releases →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-001783

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.